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Summary: HCV incidence among Australia’s HIV-positive GBM population is likely to decline 
sharply with DAA use, even with increases in risk behavior. Our model suggests reaching the 
WHO HCV elimination target ahead of time among this population is achievable. 
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ABSTRACT 
Background: HIV-positive gay and bisexual men (GBM) in Australia are well engaged in clinical 
care. We hypothesized that the World Health Organization’s hepatitis C virus (HCV) elimination 
target of an 80% reduction in incidence by 2030 may be reachable ahead of time in this 
population.  
 
Methods: We predicted the effect of treatment and behavioral changes on HCV incidence among 
HIV-positive GBM up to 2025 using a HCV transmission model parameterized with Australian 
data. We assessed the impact of changes in behavior that may facilitate HCV transmission in the 
context of different rates of direct-acting antiviral (DAA) use. 
 
Results: HCV incidence in our model increased from 0.7 per 100 person years in 2000 to 2.5 per 
100 person years in 2016, and had the same trajectory as previously reported clinical data. If the 
proportion of eligible (HCV RNA positive) patients using DAAs stays at 65%/year between 2016-
2025, with high-risk sexual behavior and injecting drug use remaining at current levels, HCV 
incidence would drop to 0.4 per 100 person years (85% decline from 2016). In the same 
treatment scenario but with substantial increases in risk behavior, HCV incidence would drop to 
0.6 per 100 person years (76% decline from 2016). If the proportion of eligible patients using 
DAAs dropped from 65%/year in 2016 to 20%/year in 2025 and risk behavior did not change, HCV 
incidence would drop to 0.7 per 100 person years (70% reduction from 2016). 
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Conclusions: Reaching the World Health Organization HCV elimination target by 2025 among 
HIV-positive GBM in Australia is achievable. 
 
Keywords: Hepatitis C virus; HIV; gay and bisexual men; Australia 
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INTRODUCTION 
Hepatitis C virus (HCV) is a major contributor to morbidity and mortality in people with HIV.[1-3] 
In Australia, which has one of the highest rates of HCV screening globally,[4] it is estimated that 
around 3,000 individuals are HIV/HCV co-infected.[4, 5] Recently, HCV incidence has increased 
among Australia’s population of HIV-infected gay and bisexual men (GBM).[6] This increase was 
mirrored by an increase in injecting drug use (IDU) [6, 7] and may also be associated with an 
increase in high-risk sexual behaviors such as fisting, use of recreational drugs, and group sex.[8, 
9]  
 
Direct-acting antiviral agents (DAAs), which rapidly reduce HCV viral load and achieve high cure 
rates, offer an unprecedented opportunity to prevent transmission. Their introduction has led 
the World Health Organization (WHO) to set the ambitious target of achieving an 80% reduction 
in global HCV incidence by 2030.[10] In Australia, the first DAAs became available under 
government subsidy to all HCV-infected adults in March 2016.[11] With rapid upscale of DAAs, 
we hypothesize that it may be possible to meet the WHOs HCV elimination target ahead of time 
in Australia’s population of HIV-positive GBM as this group is well engaged in clinical care. 
Importantly however, changes in the rate of high-risk sexual practices and IDU could jeopardize 
the anticipated benefits of DAAs.[9] 
 
We developed a mathematical model of HCV transmission among HIV-positive GBM in Australia 
to investigate the extent of DAA treatment uptake required to reach the WHO target in this 
population by 2025 and identify behavioral changes that could compromise this outcome. 
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METHODS 
HCV incidence and prevalence 
HCV incidence among Australia’s HIV-positive GBM population was estimated by sub-analysis of 
recent work on the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance 
(ACCESS) project.[6] ACCESS is a HIV/sexually transmitted infection sentinel surveillance network 
of sexual health clinics, general practice clinics, infectious disease hospital outpatient clinics, 
community-run health services, and pathology laboratories.[12] In the original analysis, 
demographic, behavioral, and clinical data were extracted from the patient management systems 
of 42 sexual health services for patients who attended between 2007 and 2015. In Australia, 
sexual health services frequently manage the care of GBM and people living with HIV. The 
ACCESS sexual health services network is broadly representative of sexual health services across 
the country. Rates of HCV testing among people living with HIV increased between 2007-2015. 
However, the most notable increase in testing rates occurred between 2013-2015 when HCV 
incidence plateaued. This indicates that the current rate of testing  is picking up most incident 
HCV infections. 
 
The past prevalence of active HCV infection among Australia’s HIV-positive GBM population (with 
and without a history of IDU) was estimated from the HIV, viral hepatitis and sexually 
transmissible infections Annual Surveillance Report [13, 14] and the Australian HIV Observational 
Database.[5] Thereafter it was projected by our HCV transmission model. 
 
HCV transmission model 
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We adopted a system of ordinary differential equations to model HCV transmission among HIV-
infected GBM (see Supplementary Material - System of ordinary differential equations). This was 
based on the model previously developed by Salazar-Vizcaya et al [9] for the Swiss GBM 
population with the addition of IDU as a means of HCV transmission. We adapted the Swiss 
model to reflect HCV transmission dynamics and risk-taking behavior among Australian HIV-
positive GBM. 
 
Supplementary Figure 1 summarizes the model structure. The population was classified into 
compartments distributed by stage of infection, risk group and enrollment in care. Risk groups 
included: 1) individuals who do not engage in high-risk sexual practices associated with HCV 
transmission and do not inject drugs; 2) individuals who do not engage in high-risk sexual 
practices associated with HCV transmission but do inject drugs; 3) individuals who do engage in 
high-risk sexual practices associated with HCV transmission but do not inject drugs; and 4) 
individuals who do engage in high-risk sexual practices associated with HCV transmission and do 
inject drugs. Each risk group included five compartments: 1) two HCV uninfected (susceptible) in 
and out of HIV care; 2) two HCV-infected in and out of care; and 3) one on HCV treatment only 
accessible for individuals in care. HCV infection could occur through sexual practices, drug 
injection within sexual contexts or outside sexual contexts. The model assumed that the 
incidence of HCV infections acquired through drug injection outside sexual contexts (εIDU) 
reflects HCV incidence in the general population of injecting drug users. The main analysis 
assumed that rollout of DAAs will be successful and result in a 90% reduction in this incidence. 
Our sensitivity analyses assessed this assumption. HCV could also be acquired in all risk groups by 
means of an external force of infection independent of risk behavior. GBM could transition 
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between risk groups. Testing rates were not explicitly included in the model but were assumed 
consistent with those that led to the incidence rate reported in Boettiger et al.[6] Treatment 
rates in the model reflect transitions from infection to treatment start, and therefore time to HCV 
diagnosis and treatment delay. Individuals who cleared HCV infection were considered 
susceptible. 
 
Model parameterization and calibration 
Model parameters were estimated using the Australian HIV Observational Database,[5] the 
Australian Gay Community Periodic Surveys,[7, 15] the Australian Needle and Syringe 
Surveys,[16] or from other published literature (Supplementary Table 1). Rates of transition to 
sexual practices associated with HCV transmission, IDU, and enrolment in HIV care were set to 
reproduce data on the frequency of such practices and coverage of antiretroviral therapy, as well 
as the fraction of GBM injecting who did this within sexual contexts. The infection rate through 
sexual practices (βsex), the prevalence of active HCV infection among GBM who did and did not 
inject drugs in the year 2000, and the baseline transition rate to IDU were fitted to HCV incidence 
between 2007 and 2015, and the prevalence of HCV antibodies in 2007 (4.7% for non-IDU and 
32.5% for IDU [5, 13]) by comparing these data with model outcomes for the HIV diagnosed 
population. The model fit was obtained by minimizing the sums of squared distances between 
model outputs and data points. These distances were calculated as the differences between 
modelled and observed values weighted to reflect measurement errors in the data. The infection 
rate through IDU (βidu) in the context of sex parties was estimated by assuming that, at the 
beginning of the simulation, the incidence of HCV in GBM engaging in this practice equaled that 
in HIV-positive GBM engaging in IDU outside the context of sex parties.  
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Between 2007 and 2015, the number of HCV RNA negative GBM newly diagnosed with HIV 
ranged between 610 to 809/year.[4] The proportion of HIV-positive GBM using antiretroviral 
therapy, our proxy for being engaged in care, increased from 60.3% in 2005 to 86.5% in 2015 
(Figure 1A).[4, 7, 8] The percentage of HIV-positive GBM injecting drugs after HIV diagnosis was 
estimated to increase from 13.9% in 2010 to 17.9% in 2015 (Figure 1B).[7] The proportion of 
individuals engaging in condomless anal intercourse (CLAI) with casual partners after HIV 
diagnosis increased from 41.4% in 2005 to 51.7% in 2015 (Figure 1C).[8, 17] Among those 
engaging in CLAI with casual partners, 65% were assumed to be engaging in high-risk sexual 
behavior though this value was varied in our sensitivity analyses. This assumption was based on 
the proportion of HIV-positive GBM included in the 2011 Sydney Gay Community Periodic Survey 
who reported CLAI with casual partners in the past 6 months and either recent fisting, recent 
group sex, recent use of party drugs for sex, or any combination of the three.[18] The percentage 
of IDU taking place in the context of high-risk sex was estimated to be 90% between 2007-2016 
(Figure 1D).[7] 
 
The percentage of individuals treated for HCV between 2007-2015 was assumed to vary between 
13.6% and 27.3% among non-injecting HIV/HCV co-infected GBM, and between 7.1% and 17.6% 
among injecting HIV/HCV co-infected GBM.[19] Treatment success in the interferon era was 
greater for HCV genotypes 2 and 3 (69.0%) compared with genotypes 1 and 4 (32.4%).[19] The 
exit rates for non-injecting HIV-positive GBM (3.7 per 100 person years) and injecting HIV-positive 
GBM (5.7 per 100 person years) were based on the number of individuals who died or were lost 
to follow-up in the Australian HIV Observational Database.[5]   
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Model scenarios 
We projected future HCV incidence and prevalence of active HCV infection based on a range of 
hypothetical changes in IDU, high-risk sexual behavior, and rates of DAA treatment uptake. 
Incidence and prevalence contour plots explored the consequences of changes in risk behavior 
under three different treatment scenarios. These were: 1) 65% of eligible (HCV RNA positive) 
patients/year start a DAA regimen (based on data from the Control and Elimination within 
Australia of Hepatitis C from people living with HIV (CEASE) study [20]) increasing exponentially 
to 100% of eligible patients/year by 2025; 2) 65% of eligible patients start a DAA regimen every 
year between 2016 and 2025; and 3) 65% of eligible patients/year start a DAA regimen 
decreasing exponentially to 20% of eligible patients/year by 2025. Treatment with DAAs was 
assumed to last 3 months on average and to result in 95% sustained virologic response, 
independent of HCV genotype.[21-24] 
 
Uncertainty analyses were performed by sampling combinations of the fitted parameters and 
iteratively solving the equations for all scenarios. Outcomes were reported as a 95% range 
around the median of these model solutions. 
 
Sensitivity analyses 
The high-risk sex/CLAI with casual partners ratio used in the main analyses (0.65, Supplementary 
Table 1) may not accurately reflect reality as the available data suggested a wide range of 
possible values for this parameter. We therefore performed further model fits and projections 
for all scenarios, where this ratio varied between 0.5 and 0.8.  
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Since the scale-up of DAAs is ongoing for HCV-infected persons who inject drugs in Australia, and 
the model assumes that HIV-positive GBM who inject drugs outside the context of high-risk sex 
could become infected with HCV via contact with this population, we assumed reductions in HCV 
incidence in the general population of injecting drug users of 90% (main analysis), 50% and 10%. 
 
Software 
Statistical analyses were performed with Stata 14 (Stata Corp., College Station, Texas). All 
algorithms were implemented in R [25], using the deSolve package [26, 27] for solving the 
differential equations, the optim package [28] for model fitting, and the FME package [29] for 
sampling model parameters to produce uncertainty estimates. 
 
RESULTS 
HCV incidence in our model increased from 0.7 (95%CI 0.5-0.8) per 100 person years in 2000 to 
2.5 (95%CI 1.4-3.5) per 100 person years in 2016. The model accurately represented previously 
reported clinical data (Figure 1E).[6] The prevalence of active HCV infection in 2016 was 
estimated to be 15.4% (95%CI 10.1-21.7). 
 
High treatment uptake scenario: DAA regimen used by 65%/year of eligible individuals in 2016 
increasing to 100%/year by 2025 
Figures 2 shows the projected changes in HCV incidence and prevalence of active HCV infection 
with differing levels of behavior change in the high treatment uptake scenario. If the proportions 
of HIV/HCV co-infected GBM engaging in high-risk sex and IDU remained at current levels, the 
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continued upscale of DAA use would cause HCV incidence to drop to 0.3 (95% range 0.3-0.4) per 
100 person years by 2025 (an 88% reduction from 2016) and the prevalence of active HCV 
infection to 0.6% (95% range 0.5-0.8); this is illustrated in Figure 3A and Figure 4. Figure 3B show 
that with substantial increases in the proportions engaged in high-risk sex and IDU (both 
increasing to 80%), the upscale of DAA use would lead to HCV incidence dropping to 0.4 (95% 
range 0.4-0.6) per 100 person years by 2025 (an 82% reduction from 2016; Figure 4) and the 
prevalence of active HCV infection dropping to 0.8% (95% range 0.6-1.1). Importantly, changes in 
the proportion engaging in IDU had a bigger impact on HCV incidence and active HCV infection 
prevalence than changes in the proportion engaging in high-risk sex as illustrated in Figure 2 by 
the more dramatic changes along the x-axes than the y-axes. This was consistent across all three 
scenarios.   
 
Stable treatment uptake scenario: DAA regimen used by 65%/year of eligible individuals in 2016 
remaining stable to 2025 
With rates of high-risk sex, IDU and DAA use remaining at current levels, HCV incidence would 
drop to 0.4 (95% range 0.3-0.5) per 100 person years (85% reduction from 2016; Figure 4) and 
the prevalence of active HCV infection would decline to 0.9% (95% range 0.7-1.3; Figures 2 and 
3A). If rates of high-risk sex and IDU were both to increase substantially while DAA use remained 
stable, HCV incidence and active HCV infection prevalence would drop to 0.6 (95% range 0.5-0.8) 
per 100 person years (76% reduction from 2016; Figure 4) and 1.2% (95% range 0.9-1.9), 
respectively (Figures 2 and 3B). 
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Low treatment uptake scenario: DAA regimen used by 65%/year of eligible individuals in 2016 
decreasing to 20%/year by 2025 
In the low treatment uptake scenario, it was estimated that by 2025 HCV incidence would drop 
to 0.7 (95% range 0.4-1.3) per 100 person years (70% reduction from 2016; Figure 4) and the 
prevalence of active HCV infection would fall to 2.6% (95% range 1.6-4.3) if high-risk sexual 
behavior and IDU did not change (Figures 2 and 3A). If the proportion engaged in high-risk sex 
reached 80% by 2025 and the proportion engaged in IDU reached 80% over the same period, 
HCV incidence would drop to 1.5 (95% range 0.7-2.6) per 100 person years (38% reduction from 
2016; Figure 4) and active HCV infection prevalence would be 3.8% (95% range 2.1-6.5) (Figures 2 
and 3B). 
 
Sensitivity Analyses 
Figure 5 shows that the reductions in HCV incidence associated with each treatment scenario did 
not vary substantially when assuming extreme values for the high-risk sex/CLAI with casual 
partners ratio. Figure 6 shows that smaller reductions in the assumed HCV incidence of the 
general population of people who inject drugs led to slightly smaller reductions in HCV incidence 
among HIV-positive GBM. 
 
DISCUSSION 
We reconstructed the HCV epidemic among HIV-positive GBM in Australia between 2007-2015 
using a mathematical transmission model based on four risk groups. We used this model to 
predict the future course of HCV incidence and active HCV infection prevalence in HIV-positive 
GBM. With treatment uptake >40% and stable risk behavior between 2016-2025, the WHO HCV 
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elimination target is likely to be reached ahead of time. However, the WHO target may not be 
met if DAA coverage declines or risk behavior increases substantially. 
 
These results are consistent with earlier work. Findings from Switzerland found that stabilization 
of high-risk behavior combined with an increase in DAA uptake could effectively reduce national 
HCV incidence and prevalence among HIV-positive GBM.[9] Importantly, the HCV epidemic 
among HIV-positive GBM in Switzerland has followed a similar trend to that in Australia.[6, 9] In 
the UK, where HIV/HCV incidence among GBM has been stable for over a decade, it has been 
shown that scaling up DAAs among this population could substantially reduce active HCV 
infection prevalence without behavioral intervention.[30]  
 
There are several key differences between our study and the work from Switzerland. Firstly, we 
added IDU as a means of HCV transmission. HCV transmission among HIV-positive GBM in 
Australia is largely driven by IDU.[6] In contrast, the fraction of reported IDU among GBM in 
Switzerland is low.[9] This proved to be critical in our model as increased rates of IDU had a 
greater potential to jeopardize the benefits of DAAs compared with increased rates of high-risk 
sex. Another key difference is that our projections were based on an increasing HCV incidence 
that was beginning to decelerate, whereas the Swiss model was based on a rapidly accelerating 
increase in HCV incidence. This could have had a profound impact on the projected effects of 
scaling up DAAs in our model. Finally, we specifically designed our analysis to evaluate whether 
HCV transmission could be reduced sufficiently to reach the WHO HCV elimination target by 
2025. With stable treatment uptake and stable risk behavior between 2016-2025, the WHO HCV 
elimination target is likely to be reached early but this could be compromised by a decline in DAA 
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coverage or a substantial increase in risk behavior. Of note, it was recently reported that the 
rapid increase in uptake of pre-exposure prophylaxis, a highly effective HIV preventative 
intervention, among GBM in Australia was accompanied by an equally rapid decrease in 
consistent condom use.[31] Whether significant behavioral changes will also result from the 
introduction of DAAs is an active area of investigation. 
 
This study has benefited from the extensive, high quality clinical and behavioral data available on 
people living with HIV in Australia. However, unlike earlier models [9, 30], we had to estimate 
many parameters using published literature rather than a single national HIV database. This may 
have reduced the internal consistency of our parameter estimates. We did not investigate 
alternative explanations for increased HCV transmissions over time, such as the emergence of 
more transmissible HCV strains or an increase in unsafe injecting practices. Phylogenetic analyses 
have revealed that many strains were involved in the early spread of HCV among HIV-positive 
GBM [32, 33] hence the emergence of a particularly transmissible HCV strain seems unlikely. In 
Australia, approximately 10% of GBM who inject drugs report recent sharing of needles; this 
percentage varied little between 2015-2017.[34] Ensuring injecting drug users continue to have 
good access to clean injecting equipment is likely to be critical to the success of DAAs as 
increased sharing of equipment could be more detrimental than an increase in the number of 
injecting drug users.  
 
Our model shows that HCV transmission among Australia’s HIV-positive GBM population will 
decline sharply with DAA use, even with substantial increases in rates of risk behavior. Achieving 
the WHO HCV elimination target by 2025 among this population appears to be achievable. The 
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validity and scope of these findings are being further investigated through the ongoing 
monitoring of treatment uptake and behavior in the CEASE study.  
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Figure 1. Trends in A) antiretroviral therapy use, B) intravenous drug use, C) high-risk sex, D) intravenous drug use in the context of high-risk 
sex, and E) hepatitis C virus incidence 
 A)-D), red dots represent parameter data with error bars representing 95% confidence intervals and black lines represent trends inputted into the model. E), 
black dots with 95% confidence intervals are from [6] and the blue line is the modelled trend with shaded region representing the modelled 95% range. ART, 
antiretroviral therapy; IDU, injecting drug use; HCV, hepatitis C virus; py, person years 
 
Figure 2. Projected hepatitis C virus incidence and prevalence of active hepatitis C virus infection in 2025 with high, stable and low rates of 
direct-acting antiviral uptake 
High treatment uptake defined as an increase from 65%/year of eligible patients using DAAs in 2016 to 100%/year in 2025. Stable uptake defined as 
remaining at 65%/year of eligible patients using DAAs between 2016 and 2025. Low uptake defined as a decrease from 65%/year of eligible patients using 
DAAs in 2016 to 20%/year in 2025. IDU, injecting drug use; HCV, hepatitis C virus; DAA, direct-acting antiviral 
 
Figure 3. Projected hepatitis C virus incidence between 2016 and 2025 with A) stable and B) increasing proportions engaging in high-risk sex 
and intravenous drug use 
Black dots with error bars representing 95% confidence intervals are from [6]. Colored lines are the modelled trends with shaded regions representing the 
modelled 95% range. Stable high-risk sex behavior and IDU defined as remaining at 35% and 20%, respectively. Increasing proportion of high-risk sex behavior 
defined as increasing from 35% in 2016 to 80% in 2025. Increasing proportion of IDU defined as increasing from 20% in 2016 to 80% in 2025. High treatment 
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uptake defined as an increase from 65%/year of eligible patients using DAAs in 2016 to 100%/year in 2025. Stable uptake defined as remaining at 65%/year of 
eligible patients using DAAs. Low uptake defined as a decrease from 65%/year of eligible patients using DAAs in 2016 to 20%/year in 2025. HCV, hepatitis C 
virus; py, person years; IDU, injecting drug use 
 
Figure 4. Percentage reduction in hepatitis C virus incidence between 2016 and 2025 with different rates of direct-acting antiviral uptake and 
stable risk behavior (solid line) or increasing proportions engaging in high-risk sex and intravenous drug use (dashed line)  
Stable high-risk sex behavior and IDU defined as remaining at 35% and 20%, respectively. Increasing proportion of high-risk sex behavior defined as increasing 
from 35% in 2016 to 80% in 2025. Increasing proportion of IDU defined as increasing from 20% in 2016 to 80% in 2025. Horizontal dashed line represents 
World Health Organization hepatitis C virus elimination target. IDU, injecting drug use 
 
Figure 5. Sensitivity analysis with high-risk sex/CLAI with casual partners ratio of A) 0.5 and B) 0.8 
Unchanged high-risk sex behaviour and IDU defined as remaining at 35% and 20%, respectively. Very high proportion of high-risk sex behaviour defined as 
increasing from 35% in 2016 to 80% in 2025. Very high proportion of IDU defined as increasing from 20% in 2016 to 80% in 2025. High treatment uptake 
defined as an increase from 65%/year of eligible patients using DAAs in 2016 to 100%/year in 2025. Stable uptake defined as remaining at 65%/year of eligible 
patients using DAAs. Low uptake defined as a decrease from 65%/year of eligible patients using DAAs in 2016 to 20%/year in 2025. Error bars represent 95% 
range. Dotted grey line represents the World Health Organization HCV elimination target for 2030. CLAI, condomless anal intercourse; HCV, hepatitis C virus; 
IDU, injecting drug use; DAA, direct acting antiviral 
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Figure 6. Sensitivity analysis with an A) 50% and B) 10% reduction in HCV incidence in the population of people who inject drugs 
Unchanged high-risk sex behaviour and IDU defined as remaining at 35% and 20%, respectively. Very high proportion of high-risk sex behaviour defined as 
increasing from 35% in 2016 to 80% in 2025. Very high proportion of IDU defined as increasing from 20% in 2016 to 80% in 2025. High treatment uptake 
defined as an increase from 65%/year of eligible patients using DAAs in 2016 to 100%/year in 2025. Stable uptake defined as remaining at 65%/year of eligible 
patients using DAAs. Low uptake defined as a decrease from 65%/year of eligible patients using DAAs in 2016 to 20%/year in 2025. Error bars represent 95% 
range. Dotted grey line represents the World Health Organization HCV elimination target for 2030. HCV, hepatitis C virus; IDU, injecting drug use; DAA, direct 
acting antiviral. 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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